GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scopus BioPharma Inc (OTCPK:SCPS) » Definitions » GF Score

Scopus BioPharma (Scopus BioPharma) GF Score : 0/100 (As of May. 01, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Scopus BioPharma GF Score?

Scopus BioPharma has the GF Score of 0, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 0/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Scopus BioPharma might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Scopus BioPharma  (OTCPK:SCPS) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.


Scopus BioPharma GF Score Related Terms

Thank you for viewing the detailed overview of Scopus BioPharma's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Scopus BioPharma (Scopus BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.
Executives
Ira Scott Greenspan director 888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
Joshua R Lamstein director, officer: Chairman 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Alan M Horsager officer: See Remarks 1021 N EVERETT STREET, GLENDALE CA 91207
Robert J Gibson director, officer: Vice Chairman 71 LANTERN RIDGE RD, NEW CANAAN CT 06840
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Iv David Weild director 22 ORIOLE AVENUE, BRONXVILLE NY 10708
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
David A. Buckel director SHARPSPRING, 550 SW 2ND AVENUE, GAINESVILLE FL 32601
Raphael Hofstein director C/O HADASSAH, P.O. BOX 12000, JERUSALEM L3 91120
Paul Hopper director 7982 DOUG HILL, SAN DIEGO CA 92127
Ashish P Sanghrajka director, officer: President 101 WALL STREET, APARTMENT 19B, NEW YORK NY 10005

Scopus BioPharma (Scopus BioPharma) Headlines

From GuruFocus

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders

By GlobeNewswire GlobeNewswire 10-08-2021

Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders

By Marketwired Marketwired 09-28-2021